Gilead profit beats Street expectations on COVID and HIV sales

Gilead profit beats Street expectations on COVID and HIV sales

By Michael Erman and Sriparna Roy

(Reuters) – Gilead Sciences Inc on Thursday reported a higher-than-expected fourth-quarter profit driven by strong demand for its HIV and cancer drugs, while COVID-19 antiviral Veklury had sales that were double Wall Street estimates.

The U.S. biotech company said adjusted profit rose to $1.67 per share, ahead of analyst expectations of $1.50, according to Refinitiv data, and up from 69 cents per share a year earlier, when it took $1.85 billion in charges mostly for a legal settlement.

Quarterly revenue rose 2% to $7.4 billion, topping analysts estimates of $6.64 billion.

It forecast 2023 sales of $26 billion to $26.5 billion, ahead of analyst expectations of $25.8 billion, and adjusted earnings of $6.60 to $7 per share. The midpoint of the earnings forecast is also above analysts estimates for $6.73 per share.

Sales of COVID-19 treatment remdesivir, sold under the brand name Veklury, were $1 billion, far beyond the $511 million analysts had expected even as they slowed 26% from the previous year.

While Veklury sales declined by about half in the United States and Europe as COVID hospitalization rates fell, they tripled in other international markets.

Gileads HIV sales increased 5% to $4.8 billion in the quarter, with Biktarvy rising 15% to $2.9 billion versus the $2.8 billion analysts expected.

Descovy sales rose 13% to $537 million, outstripping the analysts forecast of $495 million.

Gileads cancer franchise also saw sales increase by 71% to $419 million. Yescarta, a CAR-T lymphoma treatment, booked $337 million, while leukemia and lymphoma treatment Tecartus came in at $82 million.

(Reporting by Sriparna Roy in Bengaluru, Caroline Humer and Michael Erman in New York; Editing by Bill Berkrot)

GBP to USD Forecast – British Pound Continues Consolidation after BOENASDAQ, S&P 500, Dow Jones Analysis – NASDAQ Rallies As Meta Gains 28%AUDUSD Forecast – Australian Dollar Gives Up Early Push HigherDespite Relentless Selling Natural Gas Has Corrected Slightly More Than AverageSilver Price Forecast – Silver Reaches the Top of Its RangeEUR/USD, GBP/USD, AUD/USD, USD/JPY – U.S. Dollar Rebounds From Multi-Month LowsLoadingLoadingLoading